Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹2,150 cr of revenue in its latest quarter (Q1 FY27) and kept 8.1% of sales as profit.
“Performance INDIA BRANDED BUSINESS In FY25, Alembic’s India-branded business reported a performance consistent with the market, recording modest single-digit growth. The Company provides a range of branded formulations for acute and specialty therapies. Some of its brands are among the leading names in their product categories, indicating a strong position in the market.”
“is to lead the industry by being the first to are expected to accelerate innovation in important file, register, and launch, securing a competitive edge and high-value products while maintaining financial across all target markets.”
Healthier than 61% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 52
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in APLLTD?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹2,150 cr |
| Other Income | ₹15 cr |
| Total Income | ₹2,165 cr |
| Cost of Materials | ₹517 cr |
| Purchases of Stock-in-Trade | ₹121 cr |
| Inventory Change (±) | ₹-18 cr |
| Employee Benefit Expense | ₹474 cr |
| Finance Costs | ₹28 cr |
| Depreciation & Amortisation | ₹98 cr |
| Other Expenses | ₹724 cr |
| Total Expenses | ₹1,943 cr |
| Profit before Tax | ₹221 cr |
| Tax Expense | ₹50 cr |
| Share of JV / Associates | ₹39 L |
| Net Profit | ₹172 cr |
| Net margin on total income | 8.0% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 1,876 cr | 1,848 cr | 2,150 cr |
| Total income | 1,892 cr | 1,873 cr | 2,165 cr |
| Expenses | 1,686 cr | 1,731 cr | 1,943 cr |
| Profit before tax | 163 cr | 118 cr | 221 cr |
| Tax | 30 cr | -83 cr | 50 cr |
| Net profit (owners' share) | 133 cr | 202 cr | 173 cr |
| Net margin (owners' share, on revenue) | 7.1% | 10.9% | 8.1% |
| EPS (₹) | 6.76 | 10.31 | 8.80 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹12 / share | 29 Jul 2026 |
| Dividend | ₹11 / share | 29 Jul 2025 |
| Dividend | ₹11 / share | 15 Jul 2024 |
| Dividend | ₹8 / share | 28 Jul 2023 |
| Dividend | ₹10 / share | 17 Aug 2022 |
| Dividend | ₹14 / share | 19 Jul 2021 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 4 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.